Key points are not available for this paper at this time.
Use of the new staging (INRGSS) and risk classification (INRG) of neuroblastoma will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world.
Monclair et al. (Tue,) studied this question.